Loading...

MediciNova

DB:RMN
Snowflake Description

Flawless balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
RMN
DB
$470M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The last earnings update was 70 days ago. More info.


Add to Portfolio Compare Print
  • MediciNova has significant price volatility in the past 3 months.
RMN Share Price and Events
7 Day Returns
8.5%
DB:RMN
-0.1%
DE Biotechs
1%
DE Market
1 Year Returns
18.3%
DB:RMN
-7.4%
DE Biotechs
-5.6%
DE Market
RMN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
MediciNova (RMN) 8.5% 36.4% 23.5% 18.3% 50.9% 604%
DE Biotechs -0.1% 6% -6.7% -7.4% 53.2% 11.6%
DE Market 1% 6.1% 8.4% -5.6% 10.9% 13.8%
1 Year Return vs Industry and Market
  • RMN outperformed the Biotechs industry which returned -7.4% over the past year.
  • RMN outperformed the Market in Germany which returned -5.6% over the past year.
Price Volatility
RMN
Industry
5yr Volatility vs Market
Related Companies

RMN Value

 Is MediciNova undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for MediciNova. This is due to cash flow or dividend data being unavailable. The share price is €9.251.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for MediciNova's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are MediciNova's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:RMN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.36
NasdaqGM:MNOV Share Price ** NasdaqGM (2019-04-24) in USD $11.15
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.73x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.72x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of MediciNova.

DB:RMN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:MNOV Share Price ÷ EPS (both in USD)

= 11.15 ÷ -0.36

-31.25x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • MediciNova is loss making, we can't compare its value to the Europe Biotechs industry average.
  • MediciNova is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does MediciNova's expected growth come at a high price?
Raw Data
DB:RMN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -31.25x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
-19.5%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for MediciNova, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on MediciNova's assets?
Raw Data
DB:RMN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $1.74
NasdaqGM:MNOV Share Price * NasdaqGM (2019-04-24) in USD $11.15
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.72x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:RMN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:MNOV Share Price ÷ Book Value per Share (both in USD)

= 11.15 ÷ 1.74

6.42x

* Primary Listing of MediciNova.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • MediciNova is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess MediciNova's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. MediciNova has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

RMN Future Performance

 How is MediciNova expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-19.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is MediciNova expected to grow at an attractive rate?
  • Unable to compare MediciNova's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare MediciNova's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare MediciNova's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:RMN Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:RMN Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts -19.5%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:RMN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:RMN Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31
2021-12-31 0 -28 1
2020-12-31 0 -27 2
2019-12-31 0 -22 2
DB:RMN Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -9 -15
2018-09-30 -9 -16
2018-06-30 -9 -13
2018-03-31 -8 -13
2017-12-31 -7 -11
2017-09-30 -7 -11
2017-06-30 -7 -10
2017-03-31 -7 -11
2016-12-31 -7 -11
2016-09-30 -7 -12
2016-06-30 -7 -11
2016-03-31 -6 -10

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • MediciNova is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if MediciNova is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:RMN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from MediciNova Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:RMN Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 3.15 3.15 3.15 1.00
2021-12-31 -0.56 -0.56 -0.56 1.00
2020-12-31 -0.60 -0.56 -0.64 2.00
2019-12-31 -0.52 -0.45 -0.59 2.00
DB:RMN Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.36
2018-09-30 -0.40
2018-06-30 -0.34
2018-03-31 -0.35
2017-12-31 -0.32
2017-09-30 -0.32
2017-06-30 -0.29
2017-03-31 -0.31
2016-12-31 -0.33
2016-09-30 -0.38
2016-06-30 -0.36
2016-03-31 -0.36

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if MediciNova will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess MediciNova's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
MediciNova has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

RMN Past Performance

  How has MediciNova performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare MediciNova's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • MediciNova does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare MediciNova's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare MediciNova's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
MediciNova's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from MediciNova Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:RMN Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -14.68 9.96 5.63
2018-09-30 -16.07 11.93 6.57
2018-06-30 -13.05 9.80 5.47
2018-03-31 -12.69 9.69 4.98
2017-12-31 -11.16 8.80 4.22
2017-09-30 -11.01 7.40 3.66
2017-06-30 -10.09 6.83 3.28
2017-03-31 -10.50 7.17 3.34
2016-12-31 -10.87 7.36 3.52
2016-09-30 -12.15 8.34 3.84
2016-06-30 -10.92 7.39 3.54
2016-03-31 -10.01 6.63 3.37
2015-12-31 -8.85 5.81 3.02
2015-09-30 -8.49 5.58 2.89
2015-06-30 -9.22 6.03 3.19
2015-03-31 -9.06 5.84 3.23
2014-12-31 -9.20 5.96 3.26
2014-09-30 6.00 -3.40 6.00 3.41
2014-06-30 6.00 -3.30 6.00 3.31
2014-03-31 6.00 -3.96 6.55 3.42
2013-12-31 6.00 -4.03 6.66 3.37
2013-09-30 0.04 -9.88 6.70 3.21
2013-06-30 0.12 -10.02 6.82 3.29
2013-03-31 0.61 -9.51 6.27 3.83
2012-12-31 0.80 -10.96 6.73 5.01
2012-09-30 0.77 -12.03 7.12 5.68
2012-06-30 0.68 -13.55 7.77 6.48

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if MediciNova has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if MediciNova has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if MediciNova improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess MediciNova's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
MediciNova has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

RMN Health

 How is MediciNova's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up MediciNova's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • MediciNova is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • MediciNova's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of MediciNova's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • MediciNova has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from MediciNova Company Filings, last reported 3 months ago.

DB:RMN Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 73.11 0.00 62.31
2018-09-30 73.55 0.00 62.44
2018-06-30 75.59 0.00 64.16
2018-03-31 75.57 0.00 62.94
2017-12-31 38.64 0.00 27.99
2017-09-30 34.72 0.00 24.54
2017-06-30 33.39 0.00 22.89
2017-03-31 32.75 0.00 21.64
2016-12-31 34.53 0.00 24.12
2016-09-30 35.75 0.00 24.97
2016-06-30 37.37 0.00 26.57
2016-03-31 39.14 0.00 27.62
2015-12-31 32.75 0.00 22.08
2015-09-30 34.63 0.00 23.61
2015-06-30 19.95 0.00 8.58
2015-03-31 20.95 0.00 9.07
2014-12-31 22.01 0.00 11.67
2014-09-30 22.98 0.00 11.94
2014-06-30 24.80 0.00 13.50
2014-03-31 26.65 0.00 14.78
2013-12-31 25.43 0.00 6.70
2013-09-30 21.45 0.00 10.66
2013-06-30 22.95 0.00 12.02
2013-03-31 14.25 0.00 3.03
2012-12-31 14.88 0.00 4.01
2012-09-30 16.70 0.00 5.74
2012-06-30 17.87 0.00 7.26
  • MediciNova has no debt.
  • MediciNova has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • MediciNova has sufficient cash runway for more than 3 years based on current free cash flow.
  • MediciNova has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 10.7% each year.
X
Financial health checks
We assess MediciNova's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. MediciNova has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

RMN Dividends

 What is MediciNova's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from MediciNova dividends.
If you bought €2,000 of MediciNova shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate MediciNova's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate MediciNova's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:RMN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:RMN Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as MediciNova has not reported any payouts.
  • Unable to verify if MediciNova's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of MediciNova's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as MediciNova has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess MediciNova's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can MediciNova afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. MediciNova has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

RMN Management

 What is the CEO of MediciNova's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Yuichi Iwaki
COMPENSATION $2,557,279
AGE 68
TENURE AS CEO 13.6 years
CEO Bio

Dr. Yuichi Iwaki, M.D., Ph.D. is a Co-Founder of MediciNova Inc. and has been its Chief Executive Officer and President since March 2006. Dr. Iwaki is a Partner of Biotech Healthcare Partners, Inc. He was an Advisor of JAFCO Co., Ltd. He has been advising pharmaceutical companies and venture capital funds regarding research and investment strategies for over 30 years and is a Board Member of several biotechnology companies. He served as an Acting Chief Financial Officer and Acting Chief Accounting Officer of MediciNova Inc. from November 8, 2013 to April 2014. He served as an Acting Chief Executive Officer of MediciNova since September 2005 and its Acting Chief Financial Officer from September 2005 to November 2011. He served as the Chairman of MediciNova Inc., from September 26, 2000 to March 30, 2007, became its Executive Chairman in July 2005. He was a Director of Avigen since November 1994 until 2008 Dr. Iwaki serves as a Director at Biotech Healthcare Partners, Inc. He has been an Executive Director of MediciNova since September 26, 2000. From September 2001 until January 2007, Dr. Iwaki also served as consultant at MediciNova Inc. in connection with financing transactions and business development activities. He is a Director of the Transplantation Immunology and Immunogenetic Laboratory since 1992 and Intercept Pharmaceuticals, Inc. Dr. Iwaki is also a visiting professor at the Toho University School of Medicine. He is also a Member of Advisory Board of Two River Group Holdings, LLC. He served as a Director at Antyra, Inc. He has held three professorships at University of Southern California School of Medicine in the departments of urology, pathology and surgery since 1992. He is a Professor in the Department of Urology, Surgery and Pathology at Keck School of Medicine. In addition, Dr. Iwaki holds visiting professorships at the University of California, Irvine, School of Medicine; Nihon University School of Medicine, Kyushu University; and the Tokyo Women's Medical School in Japan. Prior to joining the University of Southern California School of Medicine faculty in 1992, he held professorships at the University of Pittsburgh in the Departments of Surgery and Pathology from 1989 through 1991. Dr. Iwaki is the author of more than 200 peer-reviewed publications and more than 40 books. He received a Ph.D. and an M.D. from Sapporo Medicine School in Sapporo.

CEO Compensation
  • Yuichi's compensation has increased whilst company is loss making.
  • Yuichi's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the MediciNova management team in years:

7.6
Average Tenure
52
Average Age
  • The average tenure for the MediciNova management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Yuichi Iwaki

TITLE
Co-Founder
COMPENSATION
$3M
AGE
68
TENURE
13.6 yrs

Kazuko Matsuda

TITLE
Chief Medical Officer
COMPENSATION
$2M
AGE
52
TENURE
7.6 yrs

Carla Reyes

TITLE
Chief Financial Officer
AGE
46
TENURE
0.8 yrs

John O’Neil

TITLE
Controller
Board of Directors Tenure

Average tenure and age of the MediciNova board of directors in years:

5.5
Average Tenure
61
Average Age
  • The tenure for the MediciNova board of directors is about average.
Board of Directors

Jeff Himawan

TITLE
Chairman
AGE
53
TENURE
12.1 yrs

Yuichi Iwaki

TITLE
Co-Founder
COMPENSATION
$3M
AGE
68
TENURE
18.6 yrs

Yutaka Kobayashi

TITLE
Director
COMPENSATION
$68K
AGE
54
TENURE
5.5 yrs

Yoshio Ishizaka

TITLE
Director
COMPENSATION
$78K
AGE
78
TENURE
5 yrs

Hideki Nagao

TITLE
Director
COMPENSATION
$130K
AGE
61
TENURE
1.4 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess MediciNova's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. MediciNova has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

RMN News

Simply Wall St News

RMN Company Info

Description

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective ß2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company was founded in 2000 and is headquartered in La Jolla, California.

Details
Name: MediciNova, Inc.
RMN
Exchange: DB
Founded: 2000
$420,137,711
42,171,810
Website: http://medicinova.com
Address: MediciNova, Inc.
4275 Executive Square,
Suite 300,
La Jolla,
California, 92037,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM MNOV Common Stock Nasdaq Global Market US USD 09. Feb 2005
DB RMN Common Stock Deutsche Boerse AG DE EUR 09. Feb 2005
JASDAQ 4875 Common Stock TSE JASDAQ JP JPY 09. Feb 2005
Number of employees
Current staff
Staff numbers
9
MediciNova employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/24 22:20
End of day share price update: 2019/04/24 00:00
Last estimates confirmation: 2019/04/08
Last earnings filing: 2019/02/13
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.